Abstract library

9 results for "Barbe".
#199 Magnetic Resonance Imaging (MRI) v. Endoscopic Ultrasonography (EUS) for the Detection of =10-mm Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1 (MEN1). A GTE Study
Introduction: In MEN1, the main risk factor of metastases is pancreatic tumor size. We and others recommend limiting surgery to pancreatic tumors >20 mm or growing based on their size measured with EUS.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Guillaume Cadiot
#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).
Conference:
Category: Basic
Presenting Author: MD FRANCESCA SPADA
#513 Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus
Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Francesca Spada
Authors: Spada F, Pisa E, Lorizzo K, Barberis M, ...
Keywords: mTOR
#709 Temozolomide and Capecitabine: An Effective Combination in Metastasic G2 NETs
Introduction: Treatment of neuroendocrine tumors (NETs) with chemotherapy has been validated in different studies. Recently a retrospective trial demonstrated high and durable response rate with Temozolomide and Capecitabine in 30 pancreatic NETs (pNETs).
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: María Jesús Barrio
#1110 Chemotherapy with Capecitabine plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Neoplasms (NENs): An Italian Multicenter Retrospective Analysis
Introduction: A combination of capecitabine (CAP) and temozolomide (TEM) has been successfully used as first-line treatment in pancreatic neuroendocrine neoplasms (pNENs).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: NEN, NET, chemotherapy
#1204 Clinico-Pathologic and Survival Analysis of 211 GastroEnteroPancreatic G3 Neuroendocrine Carcinomas (GEP-NECs)
Introduction: GEP-NECs show Ki67>20% and/or >20 mitoses x10 HPF. Mixed AdenoNeuroendocrine Carcinomas (MANECs) are mixed exocrine-neuroendocrine neoplasms. NECs are associated with poor prognosis but recent findings have suggested that there is a fraction of patients showing a better than expected survival rate.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: NEC, Ki67, MANEC, PROGNOSIS
#1421 Oxaliplatin-based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Introduction: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: Oxaliplatin, NETs
#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status
Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Sophie Pevny
#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus
Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Chiara Alessandra Cella
Authors: Cella C A, Barberis M, Spad F, Pisa E, ...
Keywords: Everolimus, MET, RET